Hsu Chi-yuan, Go Alan S, McCulloch Charles E, Darbinian Jeanne, Iribarren Carlos
Department of Medicine, University of California, San Francisco, San Francisco, CA 94143-0532, USA.
Clin J Am Soc Nephrol. 2007 Jan;2(1):81-8. doi: 10.2215/CJN.01950606. Epub 2006 Nov 29.
There is a limited understanding of the forces that drive the steady rise in the number of patients who receive treatment for ESRD. It was hypothesized that this is not simply due to increasing prevalence of chronic kidney disease (CKD) or changes in renal failure risk factors in the population from which ESRD cases develop. A noncurrent cohort study was conducted to quantify the change over time (per year) in the likelihood of receiving ESRD therapy in a cohort of 320,252 individuals who volunteered for health check-ups between 1964 and 1985. Initiation of ESRD treatment was ascertained using the US Renal Data System registry through 2000. A total of 1471 cases of ESRD were observed during 8,347,955 person-years of observation, with ESRD cases developing between 1973 and 2000. In unadjusted Cox proportional hazards analysis, individuals who were examined later in time had an 8% per year higher risk for progressing to receive treatment for ESRD (relative risk 1.08; 95% confidence interval 1.05 to 1.11). This temporal trend in risk for future ESRD associated with year of cohort entry (baseline examination) was not explained by increases over time in the prevalence of CKD or risk factors for renal failure. After adjustment for age, gender, race, diabetes, BP, body mass index, education level, smoking status, history of myocardial infarction, serum cholesterol, proteinuria, hematuria, and serum creatinine level, there remained an 8% per year increase in risk (relative risk 1.08; 95% confidence interval 1.06 to 1.11). Among individuals who were examined from the 1960s through the 1980s, those who were examined later were more likely to receive treatment for ESRD. This trend was not accounted for by increasing prevalence of baseline CKD or risk factors for renal failure. These findings should spur further research into other forces that drive the rise in treated ESRD.
对于促使接受终末期肾病(ESRD)治疗的患者数量稳步上升的因素,人们了解有限。据推测,这不仅仅是由于慢性肾脏病(CKD)患病率的增加,也不是因为ESRD病例所源自人群中肾衰竭风险因素的变化。开展了一项非同期队列研究,以量化在1964年至1985年间自愿参加健康检查的320,252人队列中,接受ESRD治疗可能性随时间(每年)的变化。通过美国肾脏数据系统登记处确定截至2000年ESRD治疗的起始情况。在8,347,955人年的观察期内,共观察到1471例ESRD病例,这些病例在1973年至2000年间发病。在未调整的Cox比例风险分析中,较晚接受检查的个体每年进展至接受ESRD治疗的风险高8%(相对风险1.08;95%置信区间1.05至1.11)。与队列进入年份(基线检查)相关的未来ESRD风险的这种时间趋势,无法通过CKD患病率或肾衰竭风险因素随时间的增加来解释。在调整了年龄、性别、种族、糖尿病、血压、体重指数、教育水平、吸烟状况、心肌梗死病史、血清胆固醇、蛋白尿、血尿和血清肌酐水平后,风险仍每年增加8%(相对风险1.08;95%置信区间1.06至1.11)。在20世纪60年代至80年代接受检查的个体中,较晚接受检查的个体更有可能接受ESRD治疗。这种趋势无法通过基线CKD患病率或肾衰竭风险因素的增加来解释。这些发现应促使对促使接受治疗的ESRD病例增加的其他因素展开进一步研究。